| Identification | Back Directory | [Name]
Propanamide, 2-[[[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl]amino]-, (2S)- | [CAS]
1233229-75-8 | [Synonyms]
Bliretrigine
Propanamide, 2-[[[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl]amino]-, (2S)- | [Molecular Formula]
C20H24N4O2 | [MOL File]
1233229-75-8.mol | [Molecular Weight]
352.43 |
| Chemical Properties | Back Directory | [Boiling point ]
577.5±45.0 °C(Predicted) | [density ]
1.22±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (141.87 mM; Need ultrasonic) | [form ]
Solid | [pka]
15.97±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Bliretrigine is a sodium channel blocker. Bliretrigine has the effect of relieving pain[1][2][3]. | [References]
[1] WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.
[2] Yoshihiro OYAMADA, et al. External medicinal preparation containing N2-{[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl}-L-alanineamide for treating and/or preventing peripheral neuropathic pain. Patent AU2019306705.
[3] Hironori Kinoshita, et al. Preparation of N2-[(benzimidazol-2-yl or imidazo[4,5-b]pyridin-2-yl)methyl]amino acid amide derivatives as inhibitors of sensory neuron specific sodium channel (SNS). Patent AU2009331179. |
|
|